Efficacy of Combination of IntraCoronary Bolus Abciximab and Aspiration Thrombectomy in STEMI
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The routine use of glycoprotein (Gp) IIb-IIIa inhibitor such as abciximab is not recommended
by current ACC/AHA guideline (Class IIb, level of evidence of A). This may be partly due to
potential increase of bleeding. Compared bolus injection followed by continuous infusion of
Gp IIb-IIIa inhibitor, single bolus administration was proposed to decrease bleeding
complication while maintaining decrease ischemic events. It was also reported that direct
intracoronary injection of abciximab might be superior to intravenous injection regarding
myocardial perfusion.
Aspiration thrombectomy is regarded as important adjunctive therapy in the treatment of acute
ST-elevation myocardial infarction (IIa, level of evidence of B). We hypothesized that
combination of intracoronary abciximab bolus injection and aspiration thrombectomy might
enhance adequate myocardial perfusion in patient with acute ST-elevation myocardial
infarction. We will determine whether combination of intracoronary abciximab injection and
aspiration thrombectomy is superior to each treatment only in terms of myocardial perfusion
through index of microcirculatory resistance and cardiac magnetic resonance imaging.
Phase:
Phase 4
Details
Lead Sponsor:
Yonsei University
Collaborator:
Korean Society of Interventional Cardiology
Treatments:
Abciximab Antibodies, Monoclonal Immunoglobulin Fab Fragments